88 related articles for article (PubMed ID: 16533795)
1. SMAD4 levels and allelic imbalance in 18q21 in colorectal cancer.
Watanabe T; Kanazawa T; Kazama Y; Tanaka J; Tanaka T; Ishihara S; Nagawa H
Clin Cancer Res; 2006 Mar; 12(5):1654; author reply 1654-5. PubMed ID: 16533795
[No Abstract] [Full Text] [Related]
2. SMAD4 as a prognostic marker in colorectal cancer.
Alazzouzi H; Alhopuro P; Salovaara R; Sammalkorpi H; Järvinen H; Mecklin JP; Hemminki A; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Apr; 11(7):2606-11. PubMed ID: 15814640
[TBL] [Abstract][Full Text] [Related]
3. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935
[TBL] [Abstract][Full Text] [Related]
4. SMAD4 in early onset colorectal cancer.
Perea J; García-Nebreda M; Hidalgo M; Urioste M
Colorectal Dis; 2010 Sep; 12(9):948. PubMed ID: 20456468
[No Abstract] [Full Text] [Related]
5. Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: A study matched for T- and N- classification.
Tanaka T; Watanabe T; Kazama Y; Tanaka J; Kanazawa T; Kazama S; Nagawa H
Br J Cancer; 2006 Dec; 95(11):1562-7. PubMed ID: 17088901
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer.
Jia X; Shanmugam C; Paluri RK; Jhala NC; Behring MP; Katkoori VR; Sugandha SP; Bae S; Samuel T; Manne U
Oncotarget; 2017 Mar; 8(12):20198-20212. PubMed ID: 28423626
[TBL] [Abstract][Full Text] [Related]
7. Loss of Smad4 protein expression and 18qLOH as molecular markers indicating lymph node metastasis in colorectal cancer--a study matched for tumor depth and pathology.
Tanaka T; Watanabe T; Kazama Y; Tanaka J; Kanazawa T; Kazama S; Nagawa H
J Surg Oncol; 2008 Jan; 97(1):69-73. PubMed ID: 17786972
[TBL] [Abstract][Full Text] [Related]
8. ITF-2 is disrupted via allelic loss of chromosome 18q21, and ITF-2B expression is lost at the adenoma-carcinoma transition.
Herbst A; Bommer GT; Kriegl L; Jung A; Behrens A; Csanadi E; Gerhard M; Bolz C; Riesenberg R; Zimmermann W; Dietmaier W; Wolf I; Brabletz T; Göke B; Kolligs FT
Gastroenterology; 2009 Aug; 137(2):639-48, 648.e1-9. PubMed ID: 19394332
[TBL] [Abstract][Full Text] [Related]
9. Frequent allelic imbalance on chromosome 18q21 in early superficial colorectal cancers.
Akiyama Y; Arai T; Nagasaki H; Yagi OK; Nakahata A; Nakajima T; Ohkura Y; Iwai T; Saitoh K; Yuasa Y
Jpn J Cancer Res; 1999 Dec; 90(12):1329-37. PubMed ID: 10665650
[TBL] [Abstract][Full Text] [Related]
10. Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients.
Popat S; Zhao D; Chen Z; Pan H; Shao Y; Chandler I; Houlston RS
Anticancer Res; 2007; 27(1B):627-33. PubMed ID: 17348452
[TBL] [Abstract][Full Text] [Related]
11. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
[TBL] [Abstract][Full Text] [Related]
12. Allelic status of chromosomes 17p, 18q, 22q [corrected] 3p and their clinical usefulness in colorectal cancer.
Fujita S; Baba H; Yamamoto S; Akasu T; Moriya Y; Sugano K
Anticancer Res; 2006; 26(4B):2833-40. PubMed ID: 16886602
[TBL] [Abstract][Full Text] [Related]
13. Expression of Smad4 and TGF-beta2 in colorectal carcinoma.
Kouvidou Ch; Latoufis C; Lianou E; Kouvatseas G; Kakouri E; Anagnostakis D; Vrettou-Aravani V; Betsi E; Karatapanis S
Anticancer Res; 2006; 26(4B):2901-7. PubMed ID: 16886611
[TBL] [Abstract][Full Text] [Related]
14. Expression of TGF-beta1, TbetaRII and Smad4 in colorectal carcinoma.
Xu WQ; Jiang XC; Zheng L; Yu YY; Tang JM
Exp Mol Pathol; 2007 Jun; 82(3):284-91. PubMed ID: 17289018
[TBL] [Abstract][Full Text] [Related]
15. [Biomolecular prognostic factors in colorectal cancer].
Zorcolo L
Chir Ital; 2006; 58(6):733-42. PubMed ID: 17190278
[TBL] [Abstract][Full Text] [Related]
16. The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers.
Kodach LL; Wiercinska E; de Miranda NF; Bleuming SA; Musler AR; Peppelenbosch MP; Dekker E; van den Brink GR; van Noesel CJ; Morreau H; Hommes DW; Ten Dijke P; Offerhaus GJ; Hardwick JC
Gastroenterology; 2008 May; 134(5):1332-41. PubMed ID: 18471510
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers in colorectal cancer.
Anderson GR; Brenner BM
Lancet; 2002 Jan; 359(9302):183-4. PubMed ID: 11812547
[No Abstract] [Full Text] [Related]
18. Overexpression of bone morphogenetic protein 4 enhances the invasiveness of Smad4-deficient human colorectal cancer cells.
Deng H; Ravikumar TS; Yang WL
Cancer Lett; 2009 Aug; 281(2):220-31. PubMed ID: 19321257
[TBL] [Abstract][Full Text] [Related]
19. The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors.
Ali S; Cohen C; Little JV; Sequeira JH; Mosunjac MB; Siddiqui MT
Diagn Cytopathol; 2007 Oct; 35(10):644-8. PubMed ID: 17854080
[TBL] [Abstract][Full Text] [Related]
20. PPARG: a new independent marker for colorectal cancer survival.
Girnun G
Gastroenterology; 2009 Apr; 136(4):1157-60. PubMed ID: 19236969
[No Abstract] [Full Text] [Related]
[Next] [New Search]
